<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630666</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2017-13</org_study_id>
    <nct_id>NCT03630666</nct_id>
  </id_info>
  <brief_title>Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients</brief_title>
  <acronym>OLIGOPELVIS2</acronym>
  <official_title>A Study Comparing Intermittent Androgen Depriving Therapy With Or Without Salvage High-Dose Intensity Modulation Radiotherapy (IG-IMRT)To Oligometastatic Pelvic Lymph Nodes In Biochemically-relapsing Prostate Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Direction Générale de l'Offre de Soins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of
      disease, and treatment is focused on delaying progression rather than eliminating all tumor
      burden. Local therapies, and specifically radiotherapy, have been directed at quality of life
      endpoints and not at improving survival. However, advances in imaging and systemic therapy
      have identified a population of 'oligometastatic' patients who have a lower burden of
      metastatic disease (usually ≤5 lesions), who may present an exception. This condition is
      hypothesized to occupy the hinterland between incurable metastatic disease and locoregional
      disease, where micrometastatic disease is assumed to exist and yet remain eradicable.
      Oligometastases can be detected using standard imaging but the sensitivity of these exams is
      very low for patients with a PSA below 10 ng/ml. In France, FCH PET imaging is now routinely
      available in a large majority of cancer centres. More recently, PSMA PET imaging has been
      developed.

      Since most oligometastases are now discovered at a time when conventional imaging is unable
      to detect metastases, we must rely on the literature regarding purely biochemically-relapsing
      prostate cancer patients. Three strategies have been explored: (i) observation until symptoms
      develop, (ii) early intermittent Androgen Deprivation Therapy (IADT) and (iii) continuous
      Androgen Deprivation Therapy (ADT). Recent data suggest that, of the three strategies, early
      intermittent ADT was superior in term of overall survival to observation in controlling
      metastatic prostate cancer, and this effect was similar in the biochemically-relapsing
      prostate cancer patient population.

      This phase III study will explore the role of salvage pelvic IG-IMRT combined with
      intermittent ADT (IADT) in pelvic oligometastatic patients in prolonging the first
      failure-free interval between the first and the second intermittent ADT courses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening procedures will be performed up to three months before starting IADT. After
      obtaining informed consent, patients will be randomly allocated to one of two groups:

      Experimental group: IADT + IG-IMRT Control group: IADT

      In both study arms, the first injection of IADT will be administered in hospital on the day
      of randomization. The overall duration of IADT will be six months.

      In the experimental group, patients will receive radiotherapy three months after the first
      injection of IADT.

      The overall duration of radiotherapy will be three months.

      The overall duration of IADT will be six months. It will be administered three months, +/- 15
      days prior to the first day of radiotherapy. At the completion of the six-month treatment
      period, a non-treatment interval will start if :

      there is no evidence of clinical disease progression and the PSA level is ≤ 4.00 ng/ml If the
      PSA subsequently rises above 0.20 ng/ml and is confirmed by a second measurement at least
      three weeks later, PET/CT imaging will be repeated every 6 months until a clinical failure is
      detected or until the PSA rises above 4.00 ng/ml.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>phase 3 study, randomised, open</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>90 months</time_frame>
    <description>PSA or CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>90 months</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to castration-resistance</measure>
    <time_frame>90 months</time_frame>
    <description>serum testosterone mesure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity to IADT and radiation</measure>
    <time_frame>90 months</time_frame>
    <description>evaluation with NCI-CTC AE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during treatment</measure>
    <time_frame>90 months</time_frame>
    <description>questionnaire PR25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during treatment</measure>
    <time_frame>90 months</time_frame>
    <description>questionnaire EQ-5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during treatment</measure>
    <time_frame>90 months</time_frame>
    <description>questionnaire EORTC QLQ-C30 v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>site of tumor progression</measure>
    <time_frame>90 months</time_frame>
    <description>FCH or PSMA PET at biochemical relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Oligometastasis</condition>
  <arm_group>
    <arm_group_label>IADT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one injection of IADT. The overall duration of IADT will be six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IADT+ radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IADT</intervention_name>
    <description>Patient will receive one injection of IADT at randomization</description>
    <arm_group_label>IADT</arm_group_label>
    <other_name>LH-RH (Luteinizing Hormone Releasing Hormone) agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>IADT + radiotherapy</intervention_name>
    <description>Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT</description>
    <arm_group_label>IADT+ radiotherapy</arm_group_label>
    <other_name>IG-IMRT</other_name>
    <other_name>LH-RH (Luteinizing Hormone Releasing Hormone) agonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-proven prostate adenocarcinoma

          -  Age ≥ 18 years

          -  Performance Status 0-1

          -  Prior radical prostate treatment (surgery and/or radiotherapy)

          -  ≤ 5 metastatic pelvic lymph nodes detected by FCH-PET or PSMA-PET

          -  Upper limit of metastatic lymph nodes: aortic bifurcation

          -  If ADT has been previously administered to the patient, at least 12 months must have
             elapsed between the predicted duration of the last injection and inclusion of the
             patient in the study. For this category of patients, serum testosterone must be higher
             than 6 nmol/L (50 ng/L) prior to inclusion

          -  Biochemical relapse (according to the European Association of Urology guidelines) is
             defined by :

        Following radical prostatectomy (RP), biochemical recurrence (BCR) is defined by two
        consecutive rising PSA values &gt; 0.20 ng/ml After primary radiation therapy (RT), the
        Radiation Therapy Oncology Group (RTOG) and American Society for Radiation Oncology Phoenix
        Consensus Conference definition of PSA failure is any PSA increase &gt; 2.00 ng/ml higher than
        the PSA nadir value, regardless of the serum concentration of the nadir.

          -  Having given written informed consent prior to any procedure related to the study.

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including all scheduled treatment, visits and examinations.

          -  Patient has valid health insurance

          -  Subjects who have partners of childbearing potential must be willing to use a method
             of effective birth control during treatment and for 12 months following completion of
             treatment with ADT or IG-IMRT.

        Exclusion Criteria:

          -  Bone or visceral metastases

          -  Para-aortic lymph node metastases (above the aortic bifurcation)

          -  Presence of more than five metastatic lymph nodes

          -  Evidence of local intra-prostatic relapse

          -  Evidence of prostate bed relapse in a previously irradiated region. Prostate bed
             relapses which have not been previously irradiated will not be excluded

          -  Evidence of metastasis at initial diagnosis

          -  Evidence of distant metastases beyond the pelvic lymph nodes

          -  Previous irradiation of pelvic lymph nodes

          -  Castration-resistant prostate cancer (CRPC) as defined by : a castrate serum
             testosterone &lt; 6 nmol/L (50 ng/L)

          -  Contraindications to pelvic irradiation (e.g. chronic inflammatory bowel disease)

          -  Contraindications to ADT (known hypersensitivity to any of the study drugs or
             excipients)

          -  Severe uncontrolled hypertension defined as systolic BP ≥ 160 mmHg or diastolic BP ≥
             95 mmHg). Patients with a history of hypertension are allowed provided blood pressure
             is controlled by anti-hypertensive therapy

          -  Other malignancy treated within the last 5 years (except non-melanoma skin cancer)

          -  Patients with a biochemical relapse while on active treatment with LHRH-agonist,
             LHRH-antagonist, anti-androgen, maximal androgen blockade, or oestrogen

          -  Treatment during the past month with products known to influence PSA levels (such as
             finasteride)

          -  In case of previous prostate/prostate bed radiotherapy, PET-positive lymph nodes have
             to be located outside the previous irradiation field with a maximum of 20 Gy to the
             PET-positive lymph nodes region

          -  Patients already included in another therapeutic trial with an experimental drug or
             having been given an experimental drug within a period of 30 days

          -  Disorder precluding understanding of trial information or informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>STEPHANE SUPIOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>STEPHANE SUPIOT, MD</last_name>
    <phone>02 40 67 99 00</phone>
    <phone_ext>+33</phone_ext>
    <email>stephane.supiot@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MARINE TIGREAT</last_name>
    <phone>0241352821</phone>
    <phone_ext>+33</phone_ext>
    <email>marine.tigreat@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LYSIAN CARTIER, MD</last_name>
      <email>l.cartier@isc84.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PAUL SARGOS, MD</last_name>
      <email>p.sargos@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALI HASBINI, MD</last_name>
      <email>alihasbini@oncologie-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Bourgogne</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BENJAMIN SCHIPMAN, MD</last_name>
      <email>benschipman@yahou.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GENEVIEVE LOOS, MD</last_name>
      <email>Genevieve.LOOS@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GILLES CREHANGE, MD</last_name>
      <email>GCrehange@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAVID PASQUIER, MD</last_name>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PASCAL POMMIER, MD</last_name>
      <email>pascal.pommier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DAVID AZRIA, MD</last_name>
      <email>david.azria@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Azureen de Cancerologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PHILIPPE RONCHIN, MD</last_name>
      <email>ronchinp@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>STEPHANE SUPIOT, MD</last_name>
      <phone>02 40 67 99 13</phone>
      <phone_ext>+33</phone_ext>
      <email>Stephane.Supiot@ico.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>MARINE TIGREAT</last_name>
      <phone>02 40 67 98 78</phone>
      <phone_ext>+33</phone_ext>
      <email>marine.tigreat@ico.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>XAVIER BUTHAUD, MD</last_name>
      <email>xavier.buthaud@groupeconfluent.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PHILIPPE BERGEROT, MD</last_name>
      <email>philippe.bergerot@mla.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICL Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NICOLAS MAGNE, MD</last_name>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Saint Yves</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ERIK MONPETIT, MD</last_name>
      <email>mylittle@centre-st-yves.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligometastatic pelvic lymph nod, IADT, radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

